Parkinson’s disease can begin before birth, According to the new findings, people who develop Parkinson’s disease before the age of 50 can be born with disturbed brain cells that have remained undetected for decades.

This study suggests drugs that have the potential to help improve this disease process. Parkinson’s disease can begin before birth.

Parkinson’s occurs when the brain neurons that make dopamine are substances that help coordinate the movement of disrupted or dead muscles.

Symptoms that worsen over time include slowing movement, muscle stiffness, tremors, and loss of balance.

In most cases, the exact cause of neuronal failure is unclear and no drug is known.

At least 500,000 people in the US develop Parkinson’s disease each year and their incidence increases. Although most patients are 60 and older at the time of diagnosis, around 10% are aged between 21 and 50 years.

Parkinson’s is very heartbreaking because it touches people at the peak of their lives, researchers say. This exciting new study gives us hope that one day we will be able to take the first steps to prevent this disease in high-risk individuals. Tagliati is a co-author of this study. Parkinson’s disease can begin before birth.

To conduct the study, the research team produced special stem cells, called induced pluripotent stem cells (iPSC), from cells from patients with young Parkinson’s disease.

This process involves removing adult blood cells “back in time” into a primitive embryonic state. The IPSC can then produce all types of cells in the human body that are genetically identical to the patient’s own cells.

The team used iPSC to produce dopamine neurons from each patient, then cultivated them on a plate and analyzed neuronal function.

Our technique has given us a window into the past to see how well dopamine neurons can work from the beginning of a patient’s life, the researchers said.

The researchers found two important abnormalities in the dopamine neurons on the plate:

An accumulation of protein, called alpha-synuclein, is found in most forms of Parkinson’s disease.

Non-functioning lysosomes, cellular structures that act as “junk” to break down cells and reject proteins. This damage can cause accumulation of alpha-synuclein.

It seems that dopamine neurons in these people continue to break down alpha-synuclein for 20 or 30 years and can cause Parkinson’s symptoms. Parkinson’s disease can begin before birth.

The researchers also used their iPSC model to test various drugs that can reverse the observed abnormality.

They found that the drug, PEP005, was approved by the Food and Drug Administration for the treatment of pre-existing skin conditions, lowering alpha-synuclein levels in both vascular dopamine neurons and laboratory mice.

This drug also counteracts another anomaly found in patients with dopamine neurons, namely increased levels of the active version of an enzyme called protein kinase C, although the role of this version of the enzyme in Parkinson’s is unclear.

The team also plans further research to determine whether abnormalities found in neurons in young Parkinson’s patients in this study are also present in other forms of Parkinson’s.

This study is an excellent example of how doctors and researchers from various disciplines work together to develop translation studies with the potential to help patients, researchers say.

This important work was made possible by Cedars-Sinai’s dual management as a superior academic institution and exceptional hospital.